Enzyme engineering startup Imperagen, which uses an AI-driven platform to develop high-performance enzymes, has closed a $6.4M seed funding round. The company aims to help clients improve production processes while reducing cost, time, and environmental impact.
Founded by researchers from the Manchester Institute of Biotechnology, Imperagen's integrated platform combines advanced computational modeling with automated lab testing. This closed-loop system continuously learns from real-world data, allowing for more accurate and efficient enzyme design, testing, and refinement for clients in pharma, life sciences, chemicals, and consumer goods.
